Alberto Sandiumenge1, Thiago Lisboa2, Frederic Gomez3, Pilar Hernandez4, Laura Canadell5, Jordi Rello6. 1. Critical Care Department, CIBERES, Joan XXIII University Hospital, Tarragona, Spain. Electronic address: asandiumenge@yahoo.com. 2. Critical Care Department, Hospital de Clinicas, Porto Alegre, Brazil. 3. IISPV, Microbiology Department, CIBERES, Joan XXIII University Hospital, Tarragona, Spain. 4. Epidemiology Department, CIBERES, Joan XXIII University Hospital, Tarragona, Spain. 5. Pharmacology Department, CIBERES, Joan XXIII University Hospital, Tarragona, Spain. 6. Critical Care Department, Vall d'Hebron University Hospital, Institut de Recerca Vall d'Hebron, CIBERES, Universitat Autonoma de Barcelona, Spain.
Abstract
BACKGROUND: The aim of this study was to test in the clinic whether antimicrobial diversity affects resistance of Enterococcus faecium, Staphylococcus aureus, Klebsiella species, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species (ESKAPE) pathogens in ventilator-associated pneumonia (VAP). METHODS: Three different strategies of empirical antimicrobial prescription for VAP were consecutively implemented in an ICU: patient specific (10 months); scheduling, including sequential quarterly prioritization (12 months) and restriction (12 months) of antimicrobials; and mixing (10 months). Periods were compared, measuring the antimicrobial heterogeneity index (AHI). Incidence and resistance patterns of VAP caused by ESKAPE were compared. RESULTS: Overall, 127 microbiologic VAP episodes were documented. ESKAPE VAP increased significantly during scheduling (AHI, 0.65) compared with patient-specific (AHI, 0.88) and mixing (AHI, 0.87) periods (relative risk, 2.67 and 3.84, respectively). This finding was associated with a significant (P < .05) increase of carbapenem-resistant A baumannii during the scheduling period (15.0%) compared with the patient-specific (2.4%) and mixing (0%) periods. ICU mortality of resistant patients with ESKAPE VAP was doubled that of patients without ESKAPE VAP (relative risk, 2.25; 95% CI, 1.67-9.48). Thirty-day mechanical ventilation-free days was significantly increased (5 days) in patients with resistant ESKAPE VAP. CONCLUSIONS: Antibiotic strategies promoting diversity may prevent the emergence of resistance of ESKAPE organisms, improving use of health-care resources.
BACKGROUND: The aim of this study was to test in the clinic whether antimicrobial diversity affects resistance of Enterococcus faecium, Staphylococcus aureus, Klebsiella species, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species (ESKAPE) pathogens in ventilator-associated pneumonia (VAP). METHODS: Three different strategies of empirical antimicrobial prescription for VAP were consecutively implemented in an ICU: patient specific (10 months); scheduling, including sequential quarterly prioritization (12 months) and restriction (12 months) of antimicrobials; and mixing (10 months). Periods were compared, measuring the antimicrobial heterogeneity index (AHI). Incidence and resistance patterns of VAP caused by ESKAPE were compared. RESULTS: Overall, 127 microbiologic VAP episodes were documented. ESKAPE VAP increased significantly during scheduling (AHI, 0.65) compared with patient-specific (AHI, 0.88) and mixing (AHI, 0.87) periods (relative risk, 2.67 and 3.84, respectively). This finding was associated with a significant (P < .05) increase of carbapenem-resistant A baumannii during the scheduling period (15.0%) compared with the patient-specific (2.4%) and mixing (0%) periods. ICU mortality of resistant patients with ESKAPE VAP was doubled that of patients without ESKAPE VAP (relative risk, 2.25; 95% CI, 1.67-9.48). Thirty-day mechanical ventilation-free days was significantly increased (5 days) in patients with resistant ESKAPE VAP. CONCLUSIONS: Antibiotic strategies promoting diversity may prevent the emergence of resistance of ESKAPE organisms, improving use of health-care resources.
Authors: Marta Bodro; Carlota Gudiol; Carolina Garcia-Vidal; Fe Tubau; Anna Contra; Lucía Boix; Eva Domingo-Domenech; Mariona Calvo; Jordi Carratalà Journal: Support Care Cancer Date: 2013-10-30 Impact factor: 3.603
Authors: K de With; F Allerberger; S Amann; P Apfalter; H-R Brodt; T Eckmanns; M Fellhauer; H K Geiss; O Janata; R Krause; S Lemmen; E Meyer; H Mittermayer; U Porsche; E Presterl; S Reuter; B Sinha; R Strauß; A Wechsler-Fördös; C Wenisch; W V Kern Journal: Infection Date: 2016-06 Impact factor: 3.553
Authors: Neal R Barshes; Nicholas J Clark; Deeksha Bidare; J H Dudenhoeffer; Cezarina Mindru; Maria C Rodriguez-Barradas Journal: Open Forum Infect Dis Date: 2022-09-15 Impact factor: 4.423
Authors: Pleun J van Duijn; Walter Verbrugghe; Philippe G Jorens; Fabian Spöhr; Dirk Schedler; Maria Deja; Andreas Rothbart; Djillali Annane; Christine Lawrence; Matjaz Jereb; Katja Seme; Franc Šifrer; Viktorija Tomič; Francisco Estevez; Jandira Carneiro; Stephan Harbarth; Marc J M Bonten Journal: PLoS One Date: 2022-05-03 Impact factor: 3.752
Authors: Luke S P Moore; Rachel Freeman; Mark J Gilchrist; Myriam Gharbi; Eimear T Brannigan; Hugo Donaldson; David M Livermore; Alison H Holmes Journal: J Antimicrob Chemother Date: 2014-08-12 Impact factor: 5.790
Authors: Pia Abel zur Wiesch; Roger Kouyos; Sören Abel; Wolfgang Viechtbauer; Sebastian Bonhoeffer Journal: PLoS Pathog Date: 2014-06-26 Impact factor: 6.823